Find clinical trials for Breast Cancer in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Breast Cancer trials near Hanyang, Seoul, KOR:
ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a wide patient populati ...
Phase 3
Seoul, Korea, Republic of and 4 other locations
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Seoul, Korea, Republic of and 71 other locations
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...
Phase 2
Seoul, Korea, Republic of and 63 other locations
The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast...
Phase 1, Phase 2
Seoul, Korea, Republic of and 115 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Seoul, Korea, Republic of and 226 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Seoul, Korea, Republic of and 145 other locations
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other ther ...
Phase 1
Seoul, Korea, Republic of and 36 other locations
positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. Th...
Phase 1
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 64 other locations
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast...
Phase 2, Phase 3
Seoul, Korea, Republic of and 50 other locations
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer...
Phase 1
Seoul, Korea, Republic of and 35 other locations
Clinical trials
Research sites
Resources
Legal